{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Aurora kinases : Questions médicales les plus fréquentes",
"headline": "Aurora kinases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Aurora kinases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-30",
"dateModified": "2025-03-25",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Aurora kinases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protein-Serine-Threonine Kinases",
"url": "https://questionsmedicales.fr/mesh/D017346",
"about": {
"@type": "MedicalCondition",
"name": "Protein-Serine-Threonine Kinases",
"code": {
"@type": "MedicalCode",
"code": "D017346",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Aurora kinase A",
"alternateName": "Aurora Kinase A",
"url": "https://questionsmedicales.fr/mesh/D064096",
"about": {
"@type": "MedicalCondition",
"name": "Aurora kinase A",
"code": {
"@type": "MedicalCode",
"code": "D064096",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.103.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Aurora kinase B",
"alternateName": "Aurora Kinase B",
"url": "https://questionsmedicales.fr/mesh/D064107",
"about": {
"@type": "MedicalCondition",
"name": "Aurora kinase B",
"code": {
"@type": "MedicalCode",
"code": "D064107",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.103.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Aurora kinase C",
"alternateName": "Aurora Kinase C",
"url": "https://questionsmedicales.fr/mesh/D064108",
"about": {
"@type": "MedicalCondition",
"name": "Aurora kinase C",
"code": {
"@type": "MedicalCode",
"code": "D064108",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.103.875"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Aurora kinases",
"alternateName": "Aurora Kinases",
"code": {
"@type": "MedicalCode",
"code": "D064127",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Karen Schindler",
"url": "https://questionsmedicales.fr/author/Karen%20Schindler",
"affiliation": {
"@type": "Organization",
"name": "Department of Genetics, Rutgers University, Piscataway, NJ 08854, USA."
}
},
{
"@type": "Person",
"name": "Cecilia S Blengini",
"url": "https://questionsmedicales.fr/author/Cecilia%20S%20Blengini",
"affiliation": {
"@type": "Organization",
"name": "Department of Genetics; Rutgers, The State University of New Jersey, Piscataway, New Jersey, United States of America."
}
},
{
"@type": "Person",
"name": "Mansour Aboelenain",
"url": "https://questionsmedicales.fr/author/Mansour%20Aboelenain",
"affiliation": {
"@type": "Organization",
"name": "Department of Genetics, Rutgers University, Piscataway, NJ 08854, USA."
}
},
{
"@type": "Person",
"name": "Jing Wang",
"url": "https://questionsmedicales.fr/author/Jing%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Oncology, the First Affiliated Hospital of Gannan Medical College, Ganzhou, China."
}
},
{
"@type": "Person",
"name": "Tao Guo",
"url": "https://questionsmedicales.fr/author/Tao%20Guo",
"affiliation": {
"@type": "Organization",
"name": "Department of Thoracic surgery, the First Affiliated Hospital of Dalian Medical University, Dalian, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma.",
"datePublished": "2023-09-08",
"url": "https://questionsmedicales.fr/article/37746265",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fonc.2023.1238883"
}
},
{
"@type": "ScholarlyArticle",
"name": "The miR-429 suppresses proliferation and migration in glioblastoma cells and induces cell-cycle arrest and apoptosis via modulating several target genes of ERBB signaling pathway.",
"datePublished": "2022-10-11",
"url": "https://questionsmedicales.fr/article/36219319",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11033-022-07903-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Protocol for identifying properties of ERBB receptor antagonists using the barcoded ERBBprofiler assay.",
"datePublished": "2024-04-16",
"url": "https://questionsmedicales.fr/article/38635397",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.xpro.2024.102987"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mechanisms and therapeutic targets of ErbB family receptors in hepatocellular carcinoma: a narrative review.",
"datePublished": "2024-06-27",
"url": "https://questionsmedicales.fr/article/38988928",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.21037/tcr-24-837"
}
},
{
"@type": "ScholarlyArticle",
"name": "A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.",
"datePublished": "2023-06-14",
"url": "https://questionsmedicales.fr/article/37314501",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00280-023-04545-4"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protein-Serine-Threonine Kinases",
"item": "https://questionsmedicales.fr/mesh/D017346"
},
{
"@type": "ListItem",
"position": 6,
"name": "Aurora kinases",
"item": "https://questionsmedicales.fr/mesh/D064127"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Aurora kinases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Aurora kinases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Aurora kinases",
"description": "Comment diagnostiquer une anomalie des kinases Aurora ?\nQuels marqueurs sont associés aux kinases Aurora ?\nLes kinases Aurora sont-elles liées à des cancers spécifiques ?\nQuels tests sont utilisés pour évaluer l'activité des kinases Aurora ?\nPeut-on détecter les kinases Aurora dans le sang ?",
"url": "https://questionsmedicales.fr/mesh/D064127?mesh_terms=ErbB+Receptors&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Aurora kinases",
"description": "Quels symptômes sont liés à une dysrégulation des kinases Aurora ?\nLes kinases Aurora affectent-elles la division cellulaire ?\nY a-t-il des signes précoces de cancer liés aux kinases Aurora ?\nLes kinases Aurora sont-elles impliquées dans des symptômes neurologiques ?\nComment les kinases Aurora influencent-elles la croissance tumorale ?",
"url": "https://questionsmedicales.fr/mesh/D064127?mesh_terms=ErbB+Receptors&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Aurora kinases",
"description": "Peut-on prévenir les anomalies des kinases Aurora ?\nLes dépistages réguliers aident-ils à détecter les problèmes liés aux kinases Aurora ?\nY a-t-il des facteurs de mode de vie influençant les kinases Aurora ?\nLes antioxydants aident-ils à prévenir les anomalies des kinases Aurora ?\nLes vaccinations peuvent-elles prévenir les cancers liés aux kinases Aurora ?",
"url": "https://questionsmedicales.fr/mesh/D064127?mesh_terms=ErbB+Receptors&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Aurora kinases",
"description": "Quels traitements ciblent les kinases Aurora ?\nLes inhibiteurs de kinases Aurora sont-ils efficaces ?\nQuels effets secondaires peuvent résulter des traitements ciblant les kinases Aurora ?\nLes traitements ciblant les kinases Aurora sont-ils combinés avec d'autres thérapies ?\nY a-t-il des essais cliniques sur les kinases Aurora ?",
"url": "https://questionsmedicales.fr/mesh/D064127?mesh_terms=ErbB+Receptors&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Aurora kinases",
"description": "Quelles complications peuvent survenir avec des anomalies des kinases Aurora ?\nLes anomalies des kinases Aurora augmentent-elles le risque de métastases ?\nComment les anomalies des kinases Aurora affectent-elles le pronostic ?\nLes complications des traitements ciblant les kinases Aurora sont-elles fréquentes ?\nLes anomalies des kinases Aurora peuvent-elles affecter la réponse immunitaire ?",
"url": "https://questionsmedicales.fr/mesh/D064127?mesh_terms=ErbB+Receptors&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Aurora kinases",
"description": "Quels sont les facteurs de risque associés aux anomalies des kinases Aurora ?\nL'âge influence-t-il le risque d'anomalies des kinases Aurora ?\nLe tabagisme est-il un facteur de risque pour les kinases Aurora ?\nL'alimentation joue-t-elle un rôle dans les anomalies des kinases Aurora ?\nLes infections virales sont-elles liées aux anomalies des kinases Aurora ?",
"url": "https://questionsmedicales.fr/mesh/D064127?mesh_terms=ErbB+Receptors&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie des kinases Aurora ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de tissus tumoraux peuvent révéler des anomalies."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés aux kinases Aurora ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux d'expression des kinases Aurora A et B peuvent servir de marqueurs tumoraux."
}
},
{
"@type": "Question",
"name": "Les kinases Aurora sont-elles liées à des cancers spécifiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont souvent surexprimées dans des cancers comme le sein et le poumon."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des kinases Aurora ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de phosphorylation et des analyses de Western blot sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Peut-on détecter les kinases Aurora dans le sang ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, la détection se fait principalement dans les tissus tumoraux, pas dans le sang."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une dysrégulation des kinases Aurora ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient selon le cancer, mais peuvent inclure fatigue, douleur et perte de poids."
}
},
{
"@type": "Question",
"name": "Les kinases Aurora affectent-elles la division cellulaire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles jouent un rôle clé dans la mitose, et leur dysfonction peut entraîner des anomalies cellulaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes précoces de cancer liés aux kinases Aurora ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes précoces peuvent inclure des changements inexpliqués dans le corps, mais sont souvent vagues."
}
},
{
"@type": "Question",
"name": "Les kinases Aurora sont-elles impliquées dans des symptômes neurologiques ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent un lien entre les kinases Aurora et des troubles neurologiques dans certains cancers."
}
},
{
"@type": "Question",
"name": "Comment les kinases Aurora influencent-elles la croissance tumorale ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles régulent la mitose, et leur surexpression peut conduire à une croissance tumorale incontrôlée."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies des kinases Aurora ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode spécifique, mais un mode de vie sain peut réduire le risque de cancer."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers aident-ils à détecter les problèmes liés aux kinases Aurora ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dépistages réguliers peuvent aider à détecter des cancers associés aux anomalies des kinases."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs de mode de vie influençant les kinases Aurora ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et l'exercice peuvent influencer la santé cellulaire et réduire les risques."
}
},
{
"@type": "Question",
"name": "Les antioxydants aident-ils à prévenir les anomalies des kinases Aurora ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent que les antioxydants peuvent réduire le stress oxydatif, mais des recherches sont nécessaires."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles prévenir les cancers liés aux kinases Aurora ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations, comme celles contre le HPV, peuvent réduire le risque de cancers spécifiques."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les kinases Aurora ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs spécifiques des kinases Aurora sont en développement pour traiter divers cancers."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs de kinases Aurora sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent qu'ils peuvent réduire la croissance tumorale, mais des recherches sont nécessaires."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent résulter des traitements ciblant les kinases Aurora ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure nausées, fatigue et troubles hématologiques."
}
},
{
"@type": "Question",
"name": "Les traitements ciblant les kinases Aurora sont-ils combinés avec d'autres thérapies ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont souvent combinés avec la chimiothérapie ou la radiothérapie pour améliorer l'efficacité."
}
},
{
"@type": "Question",
"name": "Y a-t-il des essais cliniques sur les kinases Aurora ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, plusieurs essais cliniques évaluent l'efficacité des inhibiteurs de kinases Aurora dans divers cancers."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des anomalies des kinases Aurora ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la progression rapide du cancer et la résistance aux traitements."
}
},
{
"@type": "Question",
"name": "Les anomalies des kinases Aurora augmentent-elles le risque de métastases ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surexpression des kinases Aurora est souvent associée à une augmentation des métastases."
}
},
{
"@type": "Question",
"name": "Comment les anomalies des kinases Aurora affectent-elles le pronostic ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont souvent liées à un pronostic défavorable en raison de la croissance tumorale agressive."
}
},
{
"@type": "Question",
"name": "Les complications des traitements ciblant les kinases Aurora sont-elles fréquentes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications comme des infections et des troubles sanguins peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les anomalies des kinases Aurora peuvent-elles affecter la réponse immunitaire ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent altérer la réponse immunitaire, rendant le corps moins efficace contre le cancer."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque associés aux anomalies des kinases Aurora ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux de cancer, l'exposition à des agents cancérigènes."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'anomalies des kinases Aurora ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque d'anomalies des kinases Aurora augmente généralement avec l'âge."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque pour les kinases Aurora ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque connu pour plusieurs types de cancer associés aux kinases."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans les anomalies des kinases Aurora ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en graisses et en sucres peut augmenter le risque de cancer et d'anomalies."
}
},
{
"@type": "Question",
"name": "Les infections virales sont-elles liées aux anomalies des kinases Aurora ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales, comme le HPV, sont associées à des cancers où les kinases Aurora sont impliquées."
}
}
]
}
]
}
Hepatocellular carcinoma (HCC) patients at advanced stages receive immunotherapy or treatment with tyrosine kinase inhibitors (TKIs) such as Sorafenib (Sora) or Lenvatinib in frontline as well as Rego...
In this study, we addressed the impact of the receptor tyrosine kinase Axl binding to its ligand Gas6 in acquiring refractoriness to TKIs. The initial responses of Axl-positive and Axl-negative cell l...
We show that HCC cells exhibiting a mesenchymal-like phenotype were less sensitive to drug treatment, linking TKI resistance to changes in epithelial plasticity. Gas6/Axl expression and activation wer...
Together, these data suggest that the inhibition of ErbBs is synthetic lethal with Rego in Axl-expressing HCC cells, showing a novel vulnerability of HCC....
Glioblastoma multiforme (GBM) is an aggressive and lethal brain cancer, which is incurable with standard cancer treatments. miRNAs have great potential to be used for gene therapy due to their ability...
Here, miR-429 was overexpressed using lentiviral vectors in U-251 and U-87 GBM cells and it was observed that the expression level of several oncogenes of the ERBB pathway, EGFR, PIK3CA, PIK3CB, KRAS,...
Altogether, miR-429 seems to be an efficient suppressor of the ERBB genetic signaling pathway and a potential therapeutic for GBM....
The ERBBprofiler assay measures compound effects on ERBB family receptors and key downstream signaling pathways that are implicated in cancer or other complex diseases. Here, we present a protocol for...
Hepatocellular carcinoma (HCC) is a highly heterogeneous and aggressive tumor. In recent years, the incidence of HCC has been increasing worldwide. Despite notable advancements in treatment methodolog...
We performed a comprehensive, narrative review of the latest literature to define the current progress of ErbB family receptors in HCC in both the pre-clinical and clinical arenas....
The ErbB family belongs to the tyrosine kinase (TK) receptor family that comprises four members. These members are closely associated with proliferation, cell cycle regulation, and migration during HC...
Through in-depth research and the application of ErbB-targeted therapy, broader avenues will be opened for the treatment of HCC and other tumors, leading to more personalized and precise treatment app...
Aberrant alterations of ERBB receptor tyrosine kinases lead to tumorigenesis. Single agent therapy targeting EGFR or HER2 has shown clinical successes, but drug resistance often develops due to aberra...
Patients with actionable somatic mutations or amplifications in ERBB genes or actionable KRAS mutations were enrolled to receive neratinib and trametinib in this phase I dose escalation trial. The pri...
Twenty patients were enrolled with a median age of 50.5 years and a median of 3 lines of prior therapy. Grade 3 treatment-related toxicities included: diarrhea (25%), vomiting (10%), nausea (5%), fati...
Neratinib and trametinib combination was toxic and had limited clinical efficacy. This may be due to suboptimal drug dosing given drug-drug interactions....
NCT03065387....
ERBB receptor tyrosine kinases are involved in development and diseases like cancer, cardiovascular, neurodevelopmental, and mental disorders. Although existing drugs target ERBB receptors, the next g...
Gallbladder cancer (GBC) is an aggressive type of digestive system cancer with a dismal outcome. Given the lack of effective treatment options, the disease rapidly reoccurs and 5-year survival rate is...
We conduct a multicentre and randomised study on afatinib combined with gemcitabine and oxaliplatin (GEMOX) in patients with ErbB pathway mutated GBC. Clinical and biological evaluation involving ErbB...
The study was approved by the medical-ethical review committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine and Renji Hospital Affiliated to Shanghai Jiao Tong Uni...
NCT04183712....
Epidermal growth factor receptor (EGFR), which is referred to as ErbB1/HER1, is the prototype of the EGFR family of receptor tyrosine kinases which also comprises ErbB2 (Neu, HER2), ErbB3 (HER3), and ...
Current therapies targeting the human epidermal growth factor receptor (HER) family, including monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs), are limited by drug resistance and sy...
Transactivation of epidermal growth factor receptors (EGFR) provides intricate control over multiple regulatory cellular processes that merge the diversity of G protein-coupled receptors (GPCRs) with ...